Ibudilast (AV-411)

  title={Ibudilast (AV-411)},
  author={Annemarie Ledeboer and Mark R Hutchinson and Linda R Watkins and Kirk W Johnson},
  journal={Expert Opinion on Investigational Drugs},
  pages={935 - 950}
The treatment of neuropathic pain is a major unresolved medical challenge. Present pharmacotherapies only have modest efficacy and numerous side effects. The use of opioid analgesics is additionally coupled with dependence and withdrawal syndromes. Ibudilast (AV-411) is a non-selective phosphodiesterase inhibitor that is also known to suppress glial cell activation. It has been used clinically for other indications with a good safety profile. As glial cell activation is considered to crucially… 

Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence

The data suggest that ibudilast may be useful for treating opioid use disorders and it may enhance the analgesic effects of oxycodone.

Anticytokine therapy in neuropathic pain management

Anticytokine agents currently on the market are effective for the treatment of mostly inflammatory pain conditions, and are starting to be introduced for neuropathic pain states; however, their use is limited by potential life-threatening complications.

Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease

Ibudilast is a relatively nonselective phosphodiesterase inhibitor which has been marketed for almost 20 years in Japan for treating asthma. More recently it has been found to have anti-inflammatory

Neuroimmune interactions and pain: focus on glial-modulating targets.

The role of glia in neuropathic pain and opioid administration is described, as well as the potential superior efficacy and wider therapeutic indices provided by drugs that modulate specific glial function via novel targets.

Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain

The failure of previously tested antioxidants, neuroprotective agents, anticonvulsants and antidepressants as therapeutic or preventative strategies are discussed, and individualized, mechanism-based therapeutic options for CIPNP associated with each of the three main drug groups are suggested.

Ibudilast for the treatment of drug addiction and other neurological conditions

A current model of ibudilast target action and a review of its translational progress and prospects as a new medication in these disorders is described.

The Effect of Morphine on Glial Cells as a Potential Therapeutic Target for Pharmacological Development of Analgesic Drugs

Newer agents targeting these receptors, including cytokine receptors, κ-opioid receptors, N-methyl-D-aspartate receptors, and the recently elucidated Toll-like receptors, all show varied but promising profiles for providing significant relief from opioid side effects, while simultaneously potentiating opioid analgesia.

Reviewand neuropathic pain - a review

The intricate link of TNF-α with other neuro-inflammatory signaling systems (e.g., chemokines and p38 MAPK) has indeed inspired a systems approach perspective for future drug development in treating neuropathic pain.


Identification of glial-mediated mechanism inducing opioid side effects includes cytokine receptor, κ-opioid receptor, NMDA receptor and toll like receptor (TLR), which is important in the complex syndrome of opioid dependence and withdrawal.

[Toll-like receptor 4: the potential therapeutic target for neuropathic pain].

The structure, function, and mechanism of Toll-like receptor 4 are reviewed as well as the development of TLR4-targeted drugs.



The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain.

The results indicate that AV411 is effective in diverse models of neuropathic pain and support further exploration of its potential as a therapeutic agent for the treatment of Neuropathic pain.

Gabapentin in the treatment of neuropathic pain

Gabapentin has antihyperalgesic and antiallodynic properties but does not have significant actions as an anti-nociceptive agent, and its mechanisms of action appear to be a complex synergy between increased GABA synthesis, non-NMDA receptor antagonism and binding to the α2δ subunit of voltage dependent calcium channels.

Emerging therapies for neuropathic pain

This update will review existing treatment options for neuropathic pain, and highlight more recent advances in the development of novel analgesics to treat this chronic disorder.

Glia: novel counter-regulators of opioid analgesia

Emerging trends in the pharmacotherapy of chronic pain

It is hoped that the decade of pain control and research will lead to an arsenal of effective and safe analgesics that will conquer the problem of chronic pain.

Neuropathic pain: symptoms, models, and mechanisms

The relationships between clinical symptoms and experimental models of peripheral neuropathic pain are described, and a framework for understanding the potential mechanisms that involve primary neuronal dysfunction as well as pathological changes in neuron‐glial signaling is provided.

Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall.

Combined with its relaxing effects on bronchial smooth muscle, antiinflammatory activity of ibudilast could favorably influence pathophysiology of asthma by antagonizing chemical mediators triggering asthmatic attacks.

Neuroimmune Activation and Neuroinflammation in Chronic Pain and Opioid Tolerance/Hyperalgesia

  • J. DeleoF. TangaV. Tawfik
  • Biology, Medicine
    The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry
  • 2004
The challenge remains in the careful perturbation of injury/opioid-induced neuroimmune activation to down-regulate this process without inhibiting beneficial CNS autoimmunity that subserves neuronal protection following injury.